Didronel

(Etidronate)

Phase 3Small molecule

VVitae Pharmaceuticals Inc., an Allergan affiliate

Didronel is one of 83 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

PreventionRecruiting

Esophageal CancerPreclinical

Active, not recruiting

PreventionPhase 3

Recruiting

Competition

Competitive Landscape

93 competitors in Esophageal Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

47 2

Eloxatin

Teva

Phase 3

32 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

58 4

Opdivo

Bristol-Myers Squibb

Phase 3

13 5

Paraplatin

AAvyxa

Phase 3

31 6

Herceptin

Roche

Phase 3

12 7

Keytruda

Merck & Co.

Phase 3

11 8

Beyfortus

BeiGene

Phase 3

8 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Perjeta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Prevention

NCT05832580

Q4 2027

Phase 2Recruiting

Calcification

NCT05662111

Clinical

Trials by Indication[1]

Calcification2 trials

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01585402·7 enrolled

Treatment of Ectopic Calcification in Fahr's Disease or Syndrome

Recruiting·UUMC Utrecht·Phase 2·NCT05662111·98 enrolled

Esophageal Cancer1 trial

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Completed·OOrganon and Co··NCT01077817·684,815 enrolled

Prevention1 trial

The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum

Recruiting·UUMC Utrecht·Phase 3·NCT05832580·76 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DIDRONEL

NDA NDA017831

Apr 20, 1987

DIDRONEL

NDA NDA019545

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Etidronate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etidronate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etidronate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019545). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Vitae Pharmaceuticals Inc., an Allergan affiliate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVitae Pharmaceuticals Inc., an Allergan affiliate

Didronel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Calcification2 trials

Esophageal Cancer1 trial

Prevention1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News